Sign up today: https://investorshub.advfn.com/?imd=278713
Followers | 971 |
Posts | 382,998 |
Boards Moderated | 6 |
Alias Born | 06/24/2011 |
Twitter Profile: | Temporarily Unavailable |
Follow on Twitter: | Follow @ Temporarily Unavailable |
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
NRx remains eligible for an additional $324 million in development and sales milestones, as well as tiered double-digit royalties upon approval and commercialization of NRX-101.
$NRXP
Companies continue to work collaboratively to advance NRX-101 through registrational trials
Loading up the dip today.
2024: Envisioning a Future of Growth and Innovation
Looking ahead to 2024, our focus will be on:
Utilizing the capital market and broadening our presence in the amusement park industry.
Enhancing our operational efficiency and refining investment strategies, with a greater emphasis on the management aspects of our business.
Increasing our investment in technology to elevate visitor experiences and improve overall customer satisfaction.
$GDHG
"As the Company's CEO, I am deeply aware of my responsibilities. We are committed to improving our operations, strengthening internal controls, and developing competitive services. Our goal is to deliver returns to our shareholders and investors.
Thank you for your continued support and trust in Golden Heaven. Together, we aim to embark on a journey of sustained growth in 2024.
Warm regards,
Qiong Jin
CEO and Chairman of Golden Heaven Group Holdings Ltd."
$GDHG
A defining moment for Golden Heaven in 2023 was our successful listing on NASDAQ on April 12, 2023. This landmark event marked a new chapter in our corporate journey. The NASDAQ listing process marked improvements in our business development, corporate governance, and risk management practices. It also helped us attract talents, strengthen our partnerships, and improve our supply chain networks.
Nice tweet today!
$IVDN: The Inflation Reduction Act allows significant tax credits for energy saving measures like our patented Insultex House Wrap (TM) which delivers the highest performance with an R-6 Rating no competitor can match. Learn more at: https://t.co/LWNDwJcXDh #Insulation #TaxCredit https://t.co/FeOCVz1Qij
— Innovative Designs, Inc (Stock: $IVDN) (@riccelli_joseph) February 13, 2024
$AVRW huge news: Avenir Wellness Solutions Issues 2024 Marketing Growth Plans to Shareholders for Seratopical Revolution Skin Care Line with Support from Nicole Kidman and Facial Plastic Surgeon Dr. Michael Persky https://finance.yahoo.com/news/avenir-wellness-solutions-issues-2024-140000098.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CBDW Signs Strategic Partnership With Flex Payment Solutions & ChatCBDW AI https://finance.yahoo.com/news/1606-corp-signs-strategic-partnership-133000308.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
.065's thin here, don't miss this one!
$CBDW
With existing platform partners CannaSite and distribution partner Cool Blue Distribution, the addition of Flex Payment Solutions to the ecosystem positions CBDW as a comprehensive AI service provider in the CBD industry. The combined expertise of these strategic partners enables CBDW to offer end-to-end solutions, from advanced AI-driven chatbot technology to secure and efficient payment processing and platform development with search engine optimization (SEO), all of the components to help grow CBD businesses and brands.
$CBDW
Greg Lambrecht, CEO of 1606 Corp., expressed enthusiasm for the collaboration, stating, "this partnership with Flex Payment Solutions marks a pivotal moment for CBDW as we expand our marketing reach to hundreds of their existing clients which will strengthen our position in the market."
$CBDW wow thanks, nice premarket news! 1606 Corp. Signs Strategic Partnership With Flex Payment Solutions & ChatCBDW AI https://finance.yahoo.com/news/1606-corp-signs-strategic-partnership-133000308.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CBDW huge news this week: 1606 Corp. Launches 2nd Major Marketing Campaign With ISO Partner Cannasite https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CBDW Cannasite, a leading provider of web design and digital marketing services in the cannabis industry, has a strong client base and significant industry connections. Their partnership with 1606 Corp aims to revolutionize the AI merchandising landscape in the cannabis sector. https://finance.yahoo.com/news/building-success-first-marketing-campaign-132252227.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CBDW +26.69% now on news! Building on success of first marketing campaign, 1606 Corp launches second one with Cannasite https://finance.yahoo.com/news/building-success-first-marketing-campaign-132252227.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CBDW +27% strong start to the week!
$CBDW is excited to announce the launch of an innovative marketing campaign in collaboration with its latest ISO partner, Cannasite. https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html
$CBDW "Our initial foray into targeted marketing campaigns yielded fantastic results, setting a high bar for future endeavors. With Cannasite, we aim to replicate and surpass this success, bringing our advanced chatbot solutions to a wider audience," said Greg Lambrecht, CEO of 1606 Corp. "The overwhelming response to our Pilot program, which quickly sold out, is a testament to the market's readiness for AI-driven enhancements in e-commerce." https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html
$CBDW time to buy! Nice news to start the week here: Building on success of first marketing campaign, 1606 Corp launches second one with Cannasite https://finance.yahoo.com/news/building-success-first-marketing-campaign-132252227.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
$CBDW is closing new ISO partnerships in the coming days. (Payment Processors!)
We're one of the fastest growing AI focused companies on the OTC & we intend on becoming #1 through partnerships & continued development.
Stay tuned this week as we continue to reach for the #1 spot by expanding our #Marketing reach 2X as we close these deals. Learn more 👉 http://cbdw.ai
#Aistock #Growthstock #Amazing #AI
With two marketing campaigns currently ongoing for #ChatCBDW this week, $CBDW is also closing new ISO partnerships in the coming days. (Payment Processors!)
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 12, 2024
We're one of the fastest growing AI focused companies on the OTC & we intend on becoming #1 through partnerships &…
Thanks!
$CBDW new tweet: With two marketing campaigns currently ongoing for #ChatCBDW this week, $CBDW is also closing new ISO partnerships in the coming days. (Payment Processors!)
We're one of the fastest growing AI focused companies on the OTC & we intend on becoming #1 through partnerships & continued development.
Stay tuned this week as we continue to reach for the #1 spot by expanding our #Marketing reach 2X as we close these deals. Learn more 👉 http://cbdw.ai
#Aistock #Growthstock #Amazing #AI
With two marketing campaigns currently ongoing for #ChatCBDW this week, $CBDW is also closing new ISO partnerships in the coming days. (Payment Processors!)
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 12, 2024
We're one of the fastest growing AI focused companies on the OTC & we intend on becoming #1 through partnerships &…
$CBDW With two marketing campaigns currently ongoing for #ChatCBDW this week, $CBDW is also closing new ISO partnerships in the coming days. (Payment Processors!)
We're one of the fastest growing AI focused companies on the OTC & we intend on becoming #1 through partnerships & continued development.
Stay tuned this week as we continue to reach for the #1 spot by expanding our #Marketing reach 2X as we close these deals. Learn more 👉 http://cbdw.ai
#Aistock #Growthstock #Amazing #AI
With two marketing campaigns currently ongoing for #ChatCBDW this week, $CBDW is also closing new ISO partnerships in the coming days. (Payment Processors!)
— CBDW.ai | A Brand by 1606 Corp (@CBDWInc) February 12, 2024
We're one of the fastest growing AI focused companies on the OTC & we intend on becoming #1 through partnerships &…
Following the remarkable success of our December marketing initiative with Cool Blue Distribution, targeting CBD merchants, we enter this new campaign with high expectations and enthusiasm. The previous campaign not only demonstrated the robust demand for ChatCBDW but also underscored the effectiveness of our marketing strategies in promoting AI chatbot solutions.
$CBDW 1606 Corp. Launches 2nd Major Marketing Campaign With ISO Partner Cannasite https://finance.yahoo.com/news/1606-corp-launches-2nd-major-133000255.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr via @YahooFinance
Building a nice position here.
$CBDW
Feb. 6, 2024 /PRNewswire/ -- 1606 Corp. (Stock Symbol: CBDW), a frontrunner in the development of AI-driven merchandising chatbots for online brands, is excited to announce the launch of an innovative marketing campaign in collaboration with its latest ISO partner, Cannasite. This targeted outreach, engaging Cannasite's extensive network of over 300 clients through email and calls, is scheduled for February 6th and 7th, 2024.
Following the remarkable success of our December marketing initiative with Cool Blue Distribution, targeting CBD merchants, we enter this new campaign with high expectations and enthusiasm. The previous campaign not only demonstrated the robust demand for ChatCBDW but also underscored the effectiveness of our marketing strategies in promoting AI chatbot solutions.
$NBIO and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates: link https://finance.yahoo.com/news/nascent-biotech-manhattan-biosolutions-collaborate-120000090.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$NBIO emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.
.10's back up, big bounce starting!
$NBIO has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.
.08 bids building here
Setting up for a big bounce off the lows now.
$NBIO .129 back up, nice and green on today's PR : Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates https://finance.yahoo.com/news/nascent-biotech-manhattan-biosolutions-collaborate-120000090.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
NBIO green on news today: Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates https://finance.yahoo.com/news/nascent-biotech-manhattan-biosolutions-collaborate-120000090.html?soc_src=social-sh&soc_trk=tw&tsrc=twtr
$NBIO announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.
$NBIO a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.
$NBIO (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.
CBDW .10+ thinning
$NBIO ACCESSWIRE / February 6, 2024 / Nascent Biotech, Inc. (OTCQB:NBIO) ("Nascent Biotech", "Nascent"), a clinical-stage biotechnology company pioneering the development of monoclonal antibodies for the treatment of various cancers and viral infections, announced today it has entered into a research collaboration agreement with Manhattan BioSolutions, Inc. (Manhattan Bio), an emerging biotech company focused on precision biologics, to explore antibody-drug conjugates (ADCs) using Nascent's lead clinical candidate pritumumab (PTB) as the tumor-targeting antibody element.
Pritumumab (PTB) is a natural human antibody. This monoclonal antibody targets extracellular form of vimentin, a protein that has been linked to cancer growth and metastasis and is overexpressed in both brain and pancreatic cancers as well as other hard tumor cancers. PTB is a targeted immunotherapy that binds to vimentin in tumors and recruits the immune system to eliminate cancer cells. PTB has demonstrated a promising safety profile and preliminary efficacy in completed Phase I study in glioblastoma patients. Nascent has been recently cleared by the FDA to begin Phase II clinical trials for brain cancer.
In preclinical experiments, PTB antibody has shown the capacity to cross the blood-brain barrier with the additional potential to transport conjugated drugs into brain tissues, and Nascent holds a patent covering this specialized delivery mechanism. Under the terms of the agreement, Manhattan Bio will perform PTB conjugations to industry standard linker-payloads and will evaluate the resulting ADCs in the in vitro cell assays. The most promising candidates will be prioritized for further development for the treatment of vimentin-positive and potential secondary targets in advanced or metastatic tumors.
Nascent CEO, Sean Carrick, commented: "We are thrilled to unlock the full disruptive potential of pritumumab against cancer by collaborating with Manhattan Bio's world-leading scientists. This collaboration serves as an exciting first step in uncovering the possibilities of better targeted cancer therapies."
"Pritumumab offers unexplored potential as an ADC vector, and we are excited to test that promise leveraging our expertise in ADC discovery and development. This could pave the way for applying our newest linker-payload innovations to pritumumab in the future" said Dr. Borys Shor, CEO of Manhattan Bio.